3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Pancreatic Neoplasms
13
Colorectal Neoplasms
13
Neoplasm Metastasis
7
Small Cell Lung Carcinoma
4
Neuroblastoma
4
Lung Neoplasms
4
Sarcoma
3
Rhabdomyosarcoma
3
Colonic Neoplasms
3
Cholangiocarcinoma
3
Biliary Tract Neoplasms
3
Stomach Neoplasms
2
Sarcoma, Ewing
2
Rectal Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Refractory Solid Tumors
1
Recurrence
1
Pathologic Complete Response
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Interventions
pembrolizumab
23
Carboplatin
23
Paclitaxel
17
Specimen Handling
15
Magnetic Resonance Spectroscopy
11
Cyclophosphamide
10
Biopsy
10
Taxes
7
Capecitabine
7
Nivolumab
6
130-nm albumin-bound paclitaxel
6
sacituzumab govitecan
5
Gemcitabine
5
Doxorubicin
5
Albumin-Bound Paclitaxel
5
Fulvestrant
4
olaparib
3
fludarabine
3
eribulin
3
durvalumab
3
atezolizumab
3
Letrozole
3
Epirubicin
3
Bevacizumab
3
veliparib
2
poly ICLC
2
pertuzumab
2
aldesleukin
2
abemaciclib
2
Trastuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Irinotecan
×
30 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled